✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Clinical Reference

Contraindications & Boxed Warning

Released: Last reviewed:

Semaglutide is contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Boxed warning: thyroid C-cell tumors (rodent studies, human relevance unknown).

Clinical reference
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Overview

Semaglutide is contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Boxed warning: thyroid C-cell tumors (rodent studies, human relevance unknown).

Related clinical pages

Key facts, checked November 20, 2026

The Wegovy label lists two contraindications: a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), and a prior serious allergic reaction to semaglutide or any ingredient. The Wegovy label lists a boxed warning about thyroid C-cell tumors in rodents and warnings for pancreatitis, gallbladder disease, low blood sugar, kidney injury, allergic reactions, diabetic eye complications, faster heart rate and suicidal thoughts. The Zepbound and Saxenda labels carry the same thyroid boxed warning. Before any GLP-1 prescription, a clinician should ask about these histories; a telehealth intake that does not ask is a red flag. Compounded products have no FDA label of their own, as FDA’s page on unapproved GLP-1 drugs notes.